EDGEWELL PERSONAL CARE Co (EPC) stock
EPCNYSEPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends September 30
$28.57+0.00 (0.00%)
Close on Oct 30, 2026Market cap $1.32BP/E –Yield –
Earnings
Edgewell Personal Care's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 12, 2026
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$570.10M
-9.1% on a year earlier
Adjusted EPS, Q3 FY2026
$0.72
$0.92 a year earlier
Latest guidance
Raised
Aug 5, 2026 · 14 items
Quarterly results
Revenue and earnings per share from each of Edgewell Personal Care's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Sep 30, 2026 | Nov 12, 2026Expected | – | – | – | – | – |
| Q3 FY2026ended Jun 30, 2026 | Aug 5, 2026before the open | $570.10M | -9.1% | $0.26 | $0.72 | Release |
| Q2 FY2026ended Mar 31, 2026 | May 6, 2026before the open | $519.50M | -10.5% | $0.09 | $0.60 | Release |
| Q1 FY2026ended Dec 31, 2025 | Feb 9, 2026before the open | $422.80M | -11.6% | -$0.63 | -$0.16 | Release |
| Q4 FY2025ended Sep 30, 2025 | Nov 13, 2025before the open | $537.20M | +3.8% | -$0.66 | $0.68 | Release |
| Q3 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $627.20M | -3.2% | $0.62 | $0.92 | Release |
| Q2 FY2025ended Mar 31, 2025 | May 7, 2025before the open | $580.70M | -3.1% | $0.60 | $0.87 | Release |
| Q1 FY2025ended Dec 31, 2024 | Feb 10, 2025before the open | $478.40M | -2.1% | -$0.04 | $0.07 | Release |
| Q4 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $517.60M | -3.1% | $0.17 | $0.72 | Release |
| Q3 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | $647.80M | -0.3% | $0.98 | $1.22 | Release |
| Q2 FY2024ended Mar 31, 2024 | May 8, 2024before the open | $599.40M | +0.2% | $0.72 | $0.88 | Release |
| Q1 FY2024ended Dec 31, 2023 | Feb 7, 2024before the open | $488.90M | +4.2% | $0.09 | $0.24 | Release |
| Q4 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | $534.10M | -0.5% | $0.57 | $0.72 | Release |
| Q3 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $650.00M | +4.2% | $1.01 | $0.98 | Release |
| Q2 FY2023ended Mar 31, 2023 | May 9, 2023before the open | $598.40M | +9.3% | $0.37 | $0.56 | Release |
| Q1 FY2023ended Dec 31, 2022 | Feb 8, 2023before the open | $469.10M | +1.3% | $0.23 | $0.31 | Release |
| Q4 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | $536.90M | -1.2% | $0.64 | $0.79 | Release |
| Q3 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $623.80M | – | $0.57 | $0.86 | Release |
| Q2 FY2022ended Mar 31, 2022 | May 10, 2022before the open | $547.70M | – | $0.43 | $0.50 | Release |
| Q1 FY2022ended Dec 31, 2021 | Feb 8, 2022before the open | $463.30M | – | $0.20 | $0.42 | Release |
| Q4 FY2021ended Sep 30, 2021 | Nov 12, 2021before the open | $543.20M | – | $0.80 | $1.01 | Release |
| Q3 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | – | Release |
| Q2 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | – | Release |
| Q1 FY2021ended Dec 31, 2020 | Feb 9, 2021before the open | – | – | – | – | Release |
| Q4 FY2020ended Sep 30, 2020 | Nov 12, 2020before the open | – | – | – | – | Filing |
| Q3 FY2020ended Jun 30, 2020 | Aug 4, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Edgewell Personal Care's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Organic net salesnon-GAAP | FY2026 | 0% – +0.5% | -1% – +2% | Narrowed | Aug 5, 2026 |
| Reported net salesGAAP | FY2026 | +1.3% – +1.8% | +0.8% – +3.8% | Narrowed | Aug 5, 2026 |
| Reported net sales | FY2026 | +0.5% – +3.5% | – | New | Feb 9, 2026 |
| Adjusted gross marginnon-GAAP | FY2026 | 20 | – | New | Aug 5, 2026 |
| Adjusted gross marginnon-GAAP | FY2026 | 60% | – | New | Nov 13, 2025 |
| Adjusted operating marginnon-GAAP | FY2026 | -80 | – | New | Aug 5, 2026 |
| Adjusted operating marginnon-GAAP | FY2026 | -50% | – | New | Nov 13, 2025 |
| Adjusted EBITDAnon-GAAP | FY2026 | $250.00M – $260.00M | $245.00M – $265.00M | Narrowed | Aug 5, 2026 |
| GAAP EPSGAAP | FY2026 | $0.00 – $0.20 | $0.00 – $0.40 | Lowered | Aug 5, 2026 |
| Adjusted EPSnon-GAAP | FY2026 | $1.80 – $2.00 | $1.70 – $2.10 | Narrowed | Aug 5, 2026 |
| Adjusted free cash flownon-GAAP | FY2026 | $80.00M – $110.00M | $80.00M – $110.00M | Reaffirmed | Aug 5, 2026 |
| Free cash flow | FY2026 | $115.00M – $145.00M | – | New | Nov 13, 2025 |
| Capital expenditures | FY2026 | 3% – 3.5% | 3% – 3.5% | Reaffirmed | Aug 5, 2026 |
| Capital expendituresnon-GAAP | FY2026 | 3% – 3.5% | – | New | Feb 9, 2026 |
| Adjusted effective tax ratenon-GAAP | FY2026 | 22% – 23% | 22% – 23% | Reaffirmed | Aug 5, 2026 |
| Adjusted net debt leveragenon-GAAP | FY2026 | 3.3 – 3.4 | 3.3 – 3.5 | Lowered | Aug 5, 2026 |
| Interest expense associated with debt | FY2026 | $70.00M | $70.00M | Raised | Aug 5, 2026 |
| Other income/expense, net | FY2026 | $26.00M | $21.00M | Lowered | Aug 5, 2026 |
| pre-tax charges | FY2026 | $92.00M | – | Raised | Aug 5, 2026 |
Guidance vs results
The last range Edgewell Personal Care gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Adjusted EPS | $2.65 | $2.54Σ4Q | Below range |
| FY2025 | EPS (GAAP) | $1.73 | $0.52Σ4Q | Below range |
Guidance history
Every forecast Edgewell Personal Care put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 5, 2026 | Capital expenditures | FY2026 | 3% – 3.5% | Reaffirmed |
| Aug 5, 2026 | Adjusted EBITDA | FY2026 | $250.00M – $260.00M | Narrowed |
| Aug 5, 2026 | Adjusted EPS | FY2026 | $1.80 – $2.00 | Narrowed |
| Aug 5, 2026 | GAAP EPS | FY2026 | $0.00 – $0.20 | Lowered |
| Aug 5, 2026 | Adjusted free cash flow | FY2026 | $80.00M – $110.00M | Reaffirmed |
| Aug 5, 2026 | Adjusted gross margin | FY2026 | 20 | New |
| Aug 5, 2026 | Adjusted operating margin | FY2026 | -80 | New |
| Aug 5, 2026 | Adjusted net debt leverage | FY2026 | 3.3 – 3.4 | Lowered |
| Aug 5, 2026 | Adjusted effective tax rate | FY2026 | 22% – 23% | Reaffirmed |
| Aug 5, 2026 | Other income/expense, net | FY2026 | $26.00M | Lowered |
| Aug 5, 2026 | Interest expense associated with debt | FY2026 | $70.00M | Raised |
| Aug 5, 2026 | pre-tax charges | FY2026 | $92.00M | Raised |
| Aug 5, 2026 | Reported net sales | FY2026 | +1.3% – +1.8% | Narrowed |
| Aug 5, 2026 | Organic net sales | FY2026 | 0% – +0.5% | Narrowed |
| May 6, 2026 | Capital expenditures | FY2026 | 3% – 3.5% | Reaffirmed |
| May 6, 2026 | Adjusted EBITDA | FY2026 | $245.00M – $265.00M | Reaffirmed |
| May 6, 2026 | Adjusted EPS | FY2026 | $1.70 – $2.10 | Reaffirmed |
| May 6, 2026 | GAAP EPS | FY2026 | $0.00 – $0.40 | Lowered |
| May 6, 2026 | Adjusted free cash flow | FY2026 | $80.00M – $110.00M | Reaffirmed |
| May 6, 2026 | Adjusted net debt leverage | FY2026 | 3.3 – 3.5 | New |
| May 6, 2026 | Adjusted effective tax rate | FY2026 | 22% – 23% | Raised |
| May 6, 2026 | Other income/expense, net | FY2026 | $21.00M | New |
| May 6, 2026 | Interest expense associated with debt | FY2026 | $70.00M | Raised |
| May 6, 2026 | Reported net sales | FY2026 | +0.8% – +3.8% | Raised |
| May 6, 2026 | Organic net sales | FY2026 | -1% – +2% | Reaffirmed |
| Feb 9, 2026 | Capital expenditures | FY2026 | 3% – 3.5% | New |
| Feb 9, 2026 | Adjusted EBITDA | FY2026 | $245.00M – $265.00M | Lowered |
| Feb 9, 2026 | Adjusted EPS | FY2026 | $1.70 – $2.10 | Lowered |
| Feb 9, 2026 | GAAP EPS | FY2026 | $0.55 – $0.95 | Lowered |
| Feb 9, 2026 | Adjusted free cash flow | FY2026 | $80.00M – $110.00M | New |
| Feb 9, 2026 | Reported net sales | FY2026 | +0.5% – +3.5% | New |
| Feb 9, 2026 | Organic net sales | FY2026 | -1% – +2% | Reaffirmed |
| Nov 13, 2025 | Capital expenditures | FY2026 | 3% – 3.5% | New |
| Nov 13, 2025 | Adjusted EBITDA | FY2026 | $290.00M – $310.00M | New |
| Nov 13, 2025 | Adjusted EPS | FY2026 | $2.15 – $2.55 | New |
| Nov 13, 2025 | GAAP EPS | FY2026 | $1.10 – $1.50 | New |
| Nov 13, 2025 | Free cash flow | FY2026 | $115.00M – $145.00M | New |
| Nov 13, 2025 | Adjusted gross margin | FY2026 | 60% | New |
| Nov 13, 2025 | Adjusted operating margin | FY2026 | -50% | New |
| Nov 13, 2025 | Adjusted effective tax rate | FY2026 | 21% – 22% | New |
| Nov 13, 2025 | Reported net sales | FY2026 | +0.5% – +3.5% | New |
| Nov 13, 2025 | Organic net sales | FY2026 | -1% – +2% | New |
| Aug 5, 2025 | Capital expenditures | FY2025 | 2.5% – 3% | New |
| Aug 5, 2025 | Adjusted EBITDA | FY2025 | $312.00M | New |
| Aug 5, 2025 | Adjusted EPS | FY2025 | $2.65 | New |
| Aug 5, 2025 | GAAP EPS | FY2025 | $1.73 | New |
| Aug 5, 2025 | Free cash flow | FY2025 | $80.00M | New |
| Aug 5, 2025 | Organic net sales | FY2025 | -1.3% | New |
| May 7, 2025 | Capital expenditures | FY2025 | 2.5% – 3% | Reaffirmed |
| May 7, 2025 | Adjusted EBITDA | FY2025 | $329.00M – $341.00M | Lowered |
| May 7, 2025 | Adjusted EPS | FY2025 | $2.85 – $3.05 | Lowered |
| May 7, 2025 | GAAP EPS | FY2025 | $2.09 – $2.29 | Lowered |
| May 7, 2025 | Free cash flow | FY2025 | $130.00M – $140.00M | Lowered |
| May 7, 2025 | Adjusted effective tax rate | FY2025 | 20% | New |
| May 7, 2025 | Interest expense associated with debt | FY2025 | $74.00M | New |
| May 7, 2025 | Total depreciation and amortization expense | FY2025 | $87.00M | Raised |
| Feb 10, 2025 | Capital expenditures | FY2025 | 2.5% – 3% | New |
| Feb 10, 2025 | Adjusted EBITDA | FY2025 | $356.00M – $368.00M | Reaffirmed |
| Feb 10, 2025 | Adjusted EPS | FY2025 | $3.15 – $3.35 | Reaffirmed |
| Feb 10, 2025 | GAAP EPS | FY2025 | $2.54 – $2.74 | Lowered |
| Feb 10, 2025 | Free cash flow | FY2025 | $185.00M | Reaffirmed |
| Feb 10, 2025 | Organic net sales | FY2025 | +1% – +3% | Reaffirmed |
| Nov 7, 2024 | Capital expenditures | FY2025 | 2.5% – 3% | New |
| Nov 7, 2024 | Adjusted EBITDA | FY2025 | $356.00M – $368.00M | New |
| Nov 7, 2024 | Adjusted EPS | FY2025 | $3.15 – $3.35 | New |
| Nov 7, 2024 | GAAP EPS | FY2025 | $2.59 – $2.79 | New |
| Nov 7, 2024 | Free cash flow | FY2025 | $185.00M | New |
| Nov 7, 2024 | Reported net sales | FY2025 | +1.7% – +3.7% | New |
| Nov 7, 2024 | Organic net sales | FY2025 | +1% – +3% | New |
| Aug 6, 2024 | Capital expenditures | FY2024 | 2.5% | Lowered |
| Aug 6, 2024 | Adjusted EBITDA | FY2024 | $356.00M | Narrowed |
| Aug 6, 2024 | Adjusted EPS | FY2024 | $3.00 | Raised |
| Aug 6, 2024 | GAAP EPS | FY2024 | $2.28 | Narrowed |
| Aug 6, 2024 | Free cash flow | FY2024 | $170.00M | Reaffirmed |
| Aug 6, 2024 | Adjusted effective tax rate | FY2024 | 22% | Reaffirmed |
| Aug 6, 2024 | Interest expense associated with debt | FY2024 | $77.00M | Lowered |
| Aug 6, 2024 | Total depreciation and amortization expense | FY2024 | $90.00M | Raised |
| Aug 6, 2024 | Organic net sales | FY2024 | +1% | Lowered |
| May 8, 2024 | Capital expenditures | FY2024 | 2.5% – 3% | Reaffirmed |
| May 8, 2024 | Adjusted EBITDA | FY2024 | $348.00M – $360.00M | Raised |
| May 8, 2024 | Adjusted EPS | FY2024 | $2.80 – $3.00 | Raised |
| May 8, 2024 | GAAP EPS | FY2024 | $2.20 – $2.40 | Reaffirmed |
| May 8, 2024 | Free cash flow | FY2024 | $170.00M | Reaffirmed |
| May 8, 2024 | Adjusted effective tax rate | FY2024 | 22% | New |
| May 8, 2024 | Other Expense, net | FY2024 | $3.00M | New |
| May 8, 2024 | Interest expense associated with debt | FY2024 | $78.00M | Raised |
| May 8, 2024 | Total depreciation and amortization expense | FY2024 | $92.00M | Raised |
| May 8, 2024 | Organic net sales | FY2024 | +2% – +4% | Reaffirmed |
| Feb 7, 2024 | Capital expenditures | FY2024 | 2.5% – 3% | Reaffirmed |
| Feb 7, 2024 | Adjusted EBITDA | FY2024 | $340.00M – $352.00M | Reaffirmed |
| Feb 7, 2024 | Adjusted EPS | FY2024 | $2.65 – $2.85 | Reaffirmed |
| Feb 7, 2024 | GAAP EPS | FY2024 | $2.20 – $2.40 | Reaffirmed |
| Feb 7, 2024 | Free cash flow | FY2024 | $170.00M | Reaffirmed |
| Feb 7, 2024 | Reported net sales | FY2024 | +1% – +3% | Reaffirmed |
| Feb 7, 2024 | Organic net sales | FY2024 | +2% – +4% | Reaffirmed |
| Nov 9, 2023 | Capital expenditures | FY2024 | 2.5% – 3% | New |
| Nov 9, 2023 | Adjusted EBITDA | FY2024 | $340.00M – $352.00M | New |
| Nov 9, 2023 | Adjusted EPS | FY2024 | $2.65 – $2.85 | New |
| Nov 9, 2023 | GAAP EPS | FY2024 | $2.20 – $2.40 | New |
| Nov 9, 2023 | Free cash flow | FY2024 | $170.00M | New |
| Nov 9, 2023 | Reported net sales | FY2024 | +1% – +3% | New |
| Nov 9, 2023 | Organic net sales | FY2024 | +2% – +4% | New |
| Aug 3, 2023 | Adjusted EBITDA | FY2023 | $320.00M – $335.00M | Reaffirmed |
| Aug 3, 2023 | Adjusted EPS | FY2023 | $2.30 – $2.50 | Reaffirmed |
| Aug 3, 2023 | GAAP EPS | FY2023 | $1.95 – $2.15 | Raised |
| Aug 3, 2023 | Free cash flow | FY2023 | $150.00M | Raised |
| Aug 3, 2023 | Adjusted effective tax rate | FY2023 | 25% | Reaffirmed |
| Aug 3, 2023 | Reported net sales | FY2023 | +2% – +4% | Reaffirmed |
| Aug 3, 2023 | Organic net sales | FY2023 | +3% – +5% | Reaffirmed |
| May 9, 2023 | Adjusted EBITDA | FY2023 | $320.00M – $335.00M | Reaffirmed |
| May 9, 2023 | Adjusted EPS | FY2023 | $2.30 – $2.50 | Reaffirmed |
| May 9, 2023 | GAAP EPS | FY2023 | $1.80 – $2.00 | Lowered |
| May 9, 2023 | Free cash flow | FY2023 | $140.00M | Reaffirmed |
| May 9, 2023 | Adjusted effective tax rate | FY2023 | 25% | Raised |
| May 9, 2023 | Reported net sales | FY2023 | +2% – +4% | Reaffirmed |
| May 9, 2023 | Organic net sales | FY2023 | +3% – +5% | Reaffirmed |
| Feb 8, 2023 | Capital expenditures | FY2023 | 3% | Reaffirmed |
| Feb 8, 2023 | Adjusted EBITDA | FY2023 | $320.00M – $335.00M | Reaffirmed |
| Feb 8, 2023 | Adjusted EPS | FY2023 | $2.30 – $2.50 | Reaffirmed |
| Feb 8, 2023 | GAAP EPS | FY2023 | $1.90 – $2.10 | Reaffirmed |
| Feb 8, 2023 | Free cash flow | FY2023 | $140.00M | Reaffirmed |
| Feb 8, 2023 | Reported net sales | FY2023 | +2% – +4% | New |
| Feb 8, 2023 | Organic net sales | FY2023 | +3% – +5% | Reaffirmed |
| Nov 10, 2022 | Capital expenditures | FY2023 | 3% | New |
| Nov 10, 2022 | Adjusted EBITDA | FY2023 | $320.00M – $335.00M | New |
| Nov 10, 2022 | Adjusted EPS | FY2023 | $2.30 – $2.50 | New |
| Nov 10, 2022 | GAAP EPS | FY2023 | $1.90 – $2.10 | New |
| Nov 10, 2022 | Free cash flow | FY2023 | $140.00M | New |
| Nov 10, 2022 | Adjusted effective tax rate | FY2023 | 24% | New |
| Nov 10, 2022 | Total depreciation and amortization expense | FY2023 | $93.00M | New |
| Nov 10, 2022 | Organic net sales | FY2023 | +3% – +5% | New |
| Aug 4, 2022 | Expected capital expenditures | FY2022 | 2.7% – 3% | Lowered |
| Aug 4, 2022 | Adjusted EBITDA | FY2022 | $335.00M – $340.00M | Narrowed |
| Aug 4, 2022 | Adjusted EPS | FY2022 | $2.50 – $2.60 | Narrowed |
| Aug 4, 2022 | GAAP EPS | FY2022 | $1.83 – $1.93 | Lowered |
| Aug 4, 2022 | Adjusted effective tax rate | FY2022 | 21% – 22% | Reaffirmed |
| Aug 4, 2022 | Total depreciation and amortization expense | FY2022 | $91.00M | Lowered |
| Aug 4, 2022 | Reported net sales | FY2022 | +4% | New |
| Aug 4, 2022 | Organic sales | FY2022 | +4% | New |
| May 10, 2022 | Expected capital expenditures | FY2022 | 3% | Reaffirmed |
| May 10, 2022 | Adjusted EBITDA | FY2022 | $330.00M – $345.00M | Lowered |
| May 10, 2022 | Adjusted EPS | FY2022 | $2.38 – $2.66 | Lowered |
| May 10, 2022 | GAAP EPS | FY2022 | $1.93 – $2.21 | Lowered |
| May 10, 2022 | Adjusted effective tax rate | FY2022 | 21% – 22% | Lowered |
| May 10, 2022 | Total depreciation and amortization expense | FY2022 | $91.50M | Lowered |
| Feb 8, 2022 | Expected capital expenditures | FY2022 | 3% | Reaffirmed |
| Feb 8, 2022 | Adjusted EBITDA | FY2022 | $357.00M – $377.00M | Lowered |
| Feb 8, 2022 | Adjusted EPS | FY2022 | $2.74 – $3.02 | Lowered |
| Feb 8, 2022 | GAAP EPS | FY2022 | $2.23 – $2.51 | Lowered |
| Feb 8, 2022 | Free cash flow | FY2022 | 100% | Reaffirmed |
| Feb 8, 2022 | Adjusted effective tax rate | FY2022 | 22% – 23% | Reaffirmed |
| Feb 8, 2022 | Total depreciation and amortization expense | FY2022 | $93.50M | New |
| Nov 12, 2021 | Capital expenditures | FY2022 | 3% | New |
| Nov 12, 2021 | Adjusted EBITDA | FY2022 | $365.00M – $385.00M | New |
| Nov 12, 2021 | Adjusted EPS | FY2022 | $2.98 – $3.26 | New |
| Nov 12, 2021 | GAAP EPS | FY2022 | $2.73 – $3.01 | New |
| Nov 12, 2021 | Free cash flow | FY2022 | 100% | New |
| Nov 12, 2021 | Adjusted effective tax rate | FY2022 | 22% – 23% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Edgewell Personal Care filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Update
- Update